OneMedNet Corporation announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company focused on EEG‑based digital biomarkers and AI research platforms for central nervous system indications.
Under the multi‑year subscription, Risorius will receive large‑scale electroencephalography (EEG) and polysomnography (PSG) waveform data paired with longitudinal clinical context. The data are regulatory‑grade, de‑identified, and designed to support Risorius’s AI‑driven biomarker development for its AI Co‑Scientist platform.
OneMedNet’s trailing‑12‑month revenue was $490,000, a 48% year‑over‑year decline, and the company reported negative operating and net margins of –1,866% and –411%, respectively. The new deal is expected to generate millions of dollars in incremental recurring revenue, a multi‑fold increase relative to current earnings and a critical step toward financial stabilization.
CEO Aaron Green said, “Risorius’ rapid decision to partner with OneMedNet underscores the value of our regulatory‑grade neuro data and continuous delivery model. Real‑World EEG and PSG waveform data, when paired with longitudinal clinical results, are foundational to the research and development of next‑generation solutions focused on solving central nervous system disorders.” CEO Sangyoon Bae added, “We chose OneMedNet because of the clear alignment with our scientific and operational needs. The combination of well‑curated EEG and PSG waveform data, meaningful longitudinal follow‑up, and a scalable licensing model provides the foundation we need to accelerate internal R&D, model validation, and development of our AI Co‑Scientist platform.”
The agreement expands OneMedNet’s subscription contract base into the neuro‑cognitive and psychiatric markets, adding a new customer segment and reinforcing the company’s strategy to grow recurring revenue through data licensing. The deal follows a record $2.79 million in 2025 bookings, a 4.1‑fold increase from the prior year, and signals momentum in the company’s shift to a subscription model.
Investors and analysts are closely watching OneMedNet’s ability to generate recurring revenue streams. The Risorius deal represents a tangible step toward improving cash flow and reducing the company’s reliance on one‑off contracts, addressing the financial headwinds that have driven its revenue decline and negative margins.
The multi‑year data licensing agreement is a significant milestone for OneMedNet, potentially transforming its financial trajectory and positioning the company for a more sustainable, recurring‑revenue business model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.